What is the appropriate dosing, administration, monitoring, and contraindications for Lokelma (sodium polystyrene sulfonate) in treating hyperkalaemia?

Lokelma (Sodium Zirconium Cyclosilicate) for Hyperkalaemia

Lokelma (sodium zirconium cyclosilicate, SZC) is the preferred potassium binder for treating hyperkalaemia, with superior safety, faster onset (1 hour), and better selectivity compared to older agents like sodium polystyrene sulfonate. 1

Dosing

Initial Treatment (Acute Hyperkalaemia)

• 10 g orally three times daily for up to 48 hours 1
• Onset of action: 1 hour (significantly faster than patiromer at 7 hours or SPS at several hours) 2
• Provides mean potassium reduction of 0.72 mEq/L within 2 hours when added to standard therapy 2

Maintenance Treatment

• Starting dose: 10 g once daily 1
• Dose range: 5 g every other day to 15 g daily 1
• Titrate in 5 g increments at intervals of 1 week or longer based on serum potassium levels 1
• Discontinue or decrease if potassium falls below target range 1

Hemodialysis Patients

• Administer only on non-dialysis days 1
• Starting dose: 5 g once daily (or 10 g if K+ >6.5 mEq/L) 1
• Monitor pre-dialysis potassium after the long interdialytic interval 1
• Assess potassium one week after initiation or dose adjustment 1

Administration

Mix entire packet contents in approximately 3 tablespoons of water, stir well, and drink immediately. 1 If powder remains, add more water and repeat until no powder is left to ensure complete dose administration.

Critical Drug Interaction Timing

Administer other oral medications at least 2 hours before or 2 hours after Lokelma to avoid binding interactions. 1 This is essential as SZC can bind other medications in the gastrointestinal tract.

Monitoring

• Initial phase: Check potassium within 48 hours of starting treatment 2
• Maintenance phase: Monitor potassium at 1-week intervals after dose adjustments 1
• Long-term: Follow guideline-directed monitoring for underlying conditions (CKD, heart failure) - typically 2-4 times yearly 3
• After normalization: Additional monitoring beyond routine comorbidity surveillance is not necessary 3
• Monitor for edema, particularly in sodium-restricted patients 1

Contraindications and Precautions

Absolute Avoidance

Avoid in patients with severe constipation, bowel obstruction, impaction, or abnormal post-operative bowel motility - Lokelma has not been studied in these conditions and may worsen gastrointestinal status. 1

Sodium Content Warning

Each 5 g dose contains approximately 400 mg sodium (though absorption extent is unknown). 1 Monitor closely in:

• Patients requiring sodium restriction
• Those prone to fluid overload (heart failure, advanced CKD)
• Edema was mild-to-moderate in trials, more common at 15 g daily dose 2

Not for Emergency Use

Do not use Lokelma for life-threatening hyperkalaemia due to delayed onset of action - use immediate interventions (insulin/glucose, calcium, dialysis) instead. 1

Adverse Effects

Most common: Gastrointestinal disorders (constipation, diarrhea, nausea, vomiting) and mild-to-moderate edema 2

Electrolyte disturbances: Hypokalemia (dose-dependent) 2

Unique benefit: Sustained increases in serum bicarbonate observed, potentially beneficial for patients with metabolic acidosis 2

Critical safety distinction: Unlike sodium polystyrene sulfonate (SPS), no serious adverse events including intestinal ischemia or colonic necrosis have been reported in randomized trials. 2 This is a major advantage, as SPS carries a 33% mortality rate in some reports and doubles the risk of serious GI events. 2, 4

Clinical Context and Advantages

Why Lokelma Over Alternatives

Lokelma is superior to older agents (SPS) and comparable alternatives (patiromer):

• Selectivity: Highly selective for potassium (also binds NH4+), unlike SPS which nonselectively binds calcium and magnesium 2
• Speed: 1-hour onset vs 7 hours for patiromer vs variable hours-to-days for SPS 2
• Safety: No fatal GI injuries reported (unlike SPS which has cases of fatal intestinal necrosis) 2, 4
• Site of action: Works in both small and large intestines (vs colon-only for alternatives) 2
• Long-term efficacy: 93% of patients maintained target potassium levels over 11 months in HARMONIZE-OLE trial 2

Enabling Guideline-Directed Medical Therapy

A critical benefit: Lokelma enables continuation and optimization of RAASi therapy (ACE inhibitors, ARBs, MRAs) in patients with CKD and heart failure. 3, 2, 5 In one RCT, 55.81% of DKD patients on SZC successfully up-titrated RAASi doses vs only 27.91% without SZC (P=0.009). 5 This is crucial because RAASi discontinuation due to hyperkalaemia increases mortality and cardiovascular events.

Duration of Therapy

Unless the cause is reversible, treatment is likely indefinite for patients with chronic conditions like CKD and heart failure. 3 The 2025 European Heart Journal guidelines emphasize that patients at high risk of recurrence require ongoing potassium binder therapy with periodic assessment of efficacy and adherence. 3

Common Pitfalls to Avoid

1. Using Lokelma for acute life-threatening hyperkalaemia - it takes 1 hour to work; use immediate interventions first 1
2. Forgetting the 2-hour separation from other oral medications - this can reduce efficacy of both Lokelma and other drugs 1
3. Inadequate water mixing - ensure complete dissolution and consumption of entire dose 1
4. Premature discontinuation after potassium normalizes - most patients need indefinite therapy 3
5. Over-monitoring - once stable, return to routine monitoring per underlying condition guidelines 3